Skip to main content
. 2014 Nov 27;466(2):151–159. doi: 10.1007/s00428-014-1688-1

Fig. 5.

Fig. 5

CEACAM6 immunoreactivity in a gastric adenocarcinoma, b colorectal adenocarcinoma, c pancreatic adenocarcinoma, d lung adenocarcinoma, e ovarian mucinous carcinoma, and f urinary bladder adenocarcinoma. (Magnification, ×200)